Skip Navigation

This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow References
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Disclaimer
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Califf, R.M.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Califf, R.M.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?


Insulin resistance: a global epidemic in need of effective therapies

R.M. Califf*

Duke Clinical Research Institute, Durham, North Carolina, U.S.A.

* Robert M. Califf, Duke Clinical Research Institute, Box 3850, Durham, NC 27710, U.S.A.

Abstract

There is a worldwide rapid increase in the prevalence of type 2 diabetes, due to factors such as improved affluence, longevity, and obesity. To prevent the development of diabetes, individuals must be identified at an early stage of risk and targeted with preventive measures such as lifestyle advice and pharmacological therapy. A key indicator of risk is impaired glucose tolerance. We have recently begun the Nateglinide And Valsartan in Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) trial to gather epidemiological data and provide insight into the protective effects of the angiotensin receptor blocker valsartan in patients with improved glucose intolerance.

Key Words: Cardiovascular risk • impaired glucose tolerance • metabolic syndrome • nateglinide • valsartan


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 JAOA: Journal of the American Osteopathic AssociationHome page
N. P. Kopyt
Slowing Progression Along the Renal Disease Continuum
J Am Osteopath Assoc, April 1, 2005; 105(4): 207 - 215.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.